Open Nav

BendaRx Corp

  • Martin Noel, BendaRx Corp

Looking for financial partners to complete the NDA of our lead candidate

  • Date:Thursday, October 18
  • Time:10:30 AM - 10:45 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:The company owns the worldwide rights of SKC 1030, a novel chemotherapeutic based on bendamustine, an anticancer agent approved to treat CLL and NHL. SKC1030 is a co-formulation of bendamustine, the active pharmaceutical ingredient (“API”) and a modified cyclodextrin, a non-toxic excipient that together form a molecular complex that is free from the toxic organic solvents which are utilized in the currently marketed formulations of the API, making SKC1030 more stable, safer and clinically more desirable for patients and health providers. SKC1030 has received ODD designation from the FDA. BendaRx intends to file a US 505(b)(2) NDA and monetize the result by selling or out-licensing the drug to a major pharma with global marketing reach. SKC 1030 is patent protected in all major markets until 2031.
  • Company Website:None
  • Company HQ City:Montreal
  • Company HQ Country:Canada
  • Company HQ State:Quebec
  • CEO/Top Company Official:Martin Noel
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :SKC 1030 for the treatment of CLL and iNHL
  • Development Phase of Primary Product:NDA Preparation / In Review
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Previous and Current Investors:Hedge fund manager, Financial advisers, HNW individual
  • Size of Last Investment Round:2.4M
  • Total Amount Raised to Date, In All Rounds:4M
Martin Noel
BendaRx Corp